Danielle Valletti, Assistant Editor

Expanded Medicaid coverage has been linked to access to early diagnosis, timely treatment, and continuity of care in breast cancer.

FDA approves difamilast (Adquey), a topical PDE4 inhibitor, expanding nonsteroidal options for mild to moderate atopic dermatitis in dermatology patients 2 years and older.

The FDA approves a once-monthly dosing schedule for amivantamab and hyaluronidase-lpuj to optimize administration and cut down infusion times.

Collaborative practice agreements let pharmacists speed multiple sclerosis therapy starts, manage labs, and boost adherence—easing provider workload.

WADA tracks GLP-1s like Ozempic, Wegovy, and Zepbound at the Olympics as pharmacists weigh muscle-loss risks and sports pharmacy guidance.

MammaPrint genomic profiling guides personalized HR-positive breast cancer treatment, helping pharmacists and oncology teams reduce chemotherapy use while protecting outcomes.

Explore emerging evidence on aspirin’s potential role in reducing cancer risk and improving survival.

Innovent’s trispecific antibody IBI3003 has received FDA fast track designation for R/R MM, supported by early clinical data showing strong efficacy and manageable safety in heavily pretreated and high-risk patients.

NCCN-backed MammaPrint stratifies HR+ breast cancer, pinpointing who needs anthracyclines and how pharmacists help personalize oncology care.

GDF15 can reshape prostate cancer prognosis and treatment; pharmacists track emerging biomarker panels and targeted therapies for metastatic disease.

Pharmacists can use collaborative practice agreements in neurology to manage multiple sclerosis medications, labs, and expand care beyond disease-modifying therapies.

The phase 3 ADRIATIC trial demonstrates that consolidation durvalumab following concurrent chemoradiotherapy improves survival while maintaining health-related quality of life.

Oncology pharmacists use MammaPrint to target anthracyclines in high-risk breast cancer, sparing others cardiotoxicity and severe nausea.

RESTORE trial data show investigational elritercept improves myelofibrosis anemia and cytopenias, reduces transfusions, and guides pharmacists on monitoring with ruxolitinib.

DPYD Testing reshapes oncology dosing for 5‑FU/capecitabine to prevent toxicity and personalize chemotherapy.

NCCN updates can guide pharmacists to tailor chemotherapy for HR+/HER2- breast cancer using MammaPrint and FLEX survival data.

Embedded pharmacy experts in neurology strengthen multiple sclerosis care through education, therapy selection, lab monitoring, and collaborative practice agreements that close gaps.

Explore how pharmacists can support patients with pancreatic cancer taking atebimetinib as Immuneering leaders and oncologists discuss tolerability, education, and survival-focused phase 3 trial goals.

Emerging ultraprecision therapies target CALR mutations in myelofibrosis, promising more effective treatments and improved patient outcomes for pharmacists.

Pharmacists enhance multiple sclerosis care through collaborative practice agreements, improving patient outcomes and bridging gaps in treatment and education.

Experts discuss how atebimetinib and adjusted chemotherapy schedules enhance tolerability and treatment duration for patients with pancreatic cancer.

Pharmacists learn how protective purchasing impacts drug shortages and discover strategies to enhance supply chain visibility and patient access to essential medications.

Dato-DXd is a promising first-line treatment for metastatic triple-negative breast cancer, enhancing patient outcomes.

Experts discuss groundbreaking data on pancreatic cancer treatment, revealing a 64% survival rate and its potential to transform patient care and outcomes.

Innovative biodegradable nanoplatforms enhance cancer therapy by integrating targeted drug delivery and real-time imaging, revolutionizing oncology practices for pharmacists.

Pharmacists play a vital role in managing multiple sclerosis treatments, enhancing patient care through clinical trials and personalized therapy options.

Zavabresib receives orphan drug designation for myelofibrosis, offering hope for patients unresponsive to current treatments and enhancing therapeutic options.

Discover groundbreaking FDA-approved treatments, including at-home depression therapy, new biosimilars, and culturally relevant pain relief options.

Atebimetinib shows promise in enhancing pancreatic cancer treatment, achieving a 64% survival rate and improving patient quality of life.